HHLR ADVISORS LTD. 13D and 13G filings for Kiniksa Pharmaceuticals, Ltd.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-14 4:39 pm Purchase | 2023-12-31 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA | HHLR ADVISORS LTD. | 3,879,426 9.900% | 338,125 (+9.55%) | Filing |
| 2023-08-18 4:32 pm Purchase | 2022-12-31 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA | HHLR ADVISORS LTD. | 3,541,301 9.900% | 917,377 (+34.96%) | Filing |
| 2023-02-14 4:08 pm Sale | 2022-12-31 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA | HHLR ADVISORS LTD. | 2,623,924 7.600% | -296,099 (-10.14%) | Filing |
| 2021-02-16 4:24 pm Purchase | 2020-12-31 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA | HHLR ADVISORS LTD. | 2,920,023 9.200% | 1,024,135 (+54.02%) | Filing |
| 2020-02-14 4:24 pm Purchase | 2019-12-31 | 13G | Kiniksa Pharmaceuticals, Ltd. KNSA | HHLR ADVISORS LTD. | 1,895,888 9.900% | 507,000 (+36.50%) | Filing |